Nectar bags ANVISA (Brazil) cGMP approval for Cephalosporin API’s manufacturing facility

15 May 2015 Evaluate

Nectar Lifesciences, the fast-growing manufacturer of generic pharmaceutical active pharmaceutical ingredients (APIs) and formulation products has received ANVISA cGMP (Current Good Manufacturing Practices) approval for Brazil for its Cephalosporin APIs’ manufacturing facility in Dera Bassi, Punjab. The regulatory authority concluded that the facility, systems and practices comply with ANVISA cGMP requirements.

The facility is already approved by various international regulatory agencies such as US-FDA, MCC - South Africa, PMDA-Japan, OGYI-Hungary and KFDA- South Korea.

Brazil market for Cephalosporin’s is currently valued at $300 million between injectable and oral molecules. The company has highest capacities globally of all the approved molecules in Cephalosporin. This approval opens up very valuable market for NecLife for API’s as well as formulations for which Unit-6 located in Baddi is already approved by the ANVISA authority.

Nectar Lifesciences is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs).



Nectar Lifesciences Share Price

39.11 1.76 (4.71%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.